After the failure by Pfizer and the Chinese government to reach an agreement on including COVID medicine Paxlovid in the state health insurance plan, there are some discussions in China on whether compulsory licensing is justified as cases are surging in the nation.

You don't have access to this post on China Trade Monitor at the moment, but if you upgrade your account you'll be able to see the whole thing, as well as all the other posts in the archive! Subscribing only takes a few seconds and will give you immediate access.

This post is for subscribers only

Subscribe now